Genome editing of CCR5 by AsCpf1 renders CD4+ T cells resistance to HIV-1 infection

Cell & Bioscience
Zhepeng LiuGeng Tian

Abstract

The chemokine receptor CCR5 is one of the co-receptor of HIV-1 infection. People with homozygous CCR5Δ32 deletion resist HIV-1 infection, which makes the CCR5 an important target for HIV-1 gene therapy. Although the CRISPR/Cas9 has ever been used for HIV-1 study, the newly developed CRISPR/AsCpf1 has never been utilized in HIV-1 co-receptor disruption. The CRISPR/Cpf1 system shows many advantages over CRISPR/Cas9, such as lower off-target, small size of nuclease, easy sgRNA design for multiplex gene editing, etc. Therefore, the CRISPR/Cpf1 mediated gene editing will confer a more specific and safe strategy in HIV-1 co-receptor disruption. Here, we demonstrated that CRISPR/AsCpf1 could ablate the main co-receptor of HIV-1 infection-CCR5 efficiently with two screened sgRNAs via different delivery strategies (lentivirus, adenovirus). The edited cells resisted R5-tropic HIV-1 infection but not X4-tropic HIV-1 infection compared with the control group in different cell types of HIV-1 study (TZM.bl, SupT1-R5, Primary CD4+T cells). Meanwhile, the edited cells exhibited selective advantage over unedited cells while under the pressure of R5-tropic HIV-1. Furthermore, we clarified that the predicted off-target sites of selected sgRNAs we...Continue Reading

References

Jun 18, 1998·Cell·D C Chan, P S Kim
Feb 14, 2009·The New England Journal of Medicine·Gero HütterEckhard Thiel
Mar 7, 2009·Science·Douglas D RichmanRoger J Pomerantz
Aug 5, 2011·Nucleic Acids Research·Claudio MussolinoToni Cathomen
Aug 8, 2012·Trends in Immunology·Christine M DurandRobert F Siliciano
Jan 5, 2013·Science·Prashant MaliGeorge M Church
Oct 29, 2013·Nature Reviews. Microbiology·Françoise Barré-SinoussiJean-François Delfraissy
Mar 7, 2014·The New England Journal of Medicine·Pablo TebasCarl H June
Jun 9, 2016·Nature Biotechnology·Daesik KimJin-Soo Kim
Jun 28, 2016·Nature Biotechnology·Benjamin P KleinstiverJ Keith Joung
Dec 6, 2016·Nature Biotechnology·Bernd ZetscheFeng Zhang
Mar 21, 2017·Molecular Plant·Mugui WangJian-Kang Zhu
Feb 26, 2019·Nature Methods·Xiaoyun DaiSidi Chen
Mar 6, 2019·Nature·Ravindra K GuptaEduardo Olavarria
Sep 12, 2019·The New England Journal of Medicine·Lei XuHu Chen

❮ Previous
Next ❯

Citations

Sep 27, 2020·Genes·Ilayda AtesRenee N Cottle
Nov 22, 2020·Methods and Protocols·Mateusz Kotowski, Sumana Sharma

❮ Previous
Next ❯

Methods Mentioned

BETA
gene
PCR
flow cytometry
ELISA
FCS
cleavage
electrophoresis

Software Mentioned

SPSS
CytExpert
CCTop

Related Concepts

Related Feeds

CRISPR Genome Editing & Therapy

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of this system for gene editing and therapy in human diseases.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis